Filed pursuant to Rule 424(b)(2)
Registration No. 333-279371
PROSPECTUS SUPPLEMENT
(to Prospectus dated June 5, 2024)
Danimer Scientific, Inc.
Up To 5,939,560 Shares of Common Stock
Danimer Scientific, Inc. (the
“Company,” “Danimer,” “we,” “our,” or “us”) is offering up to 5,939,560 shares
of its Class A common stock, $0.0001 par value per share (“Common Stock”) directly to B. Dyson Capital Advisors and/or its
affiliates (collectively, the “Advisor”) from time to time in consideration of financial and investment banking advisory services
(the “Services”) provided by the Advisor to the Company.
Our Common Stock is listed
on The New York Stock Exchange under the symbol “DNMR”. On July 11, 2024, the last reported sale price of our Common Stock
on the New York Stock Exchange (the “NYSE”) was $0.6045 per share.
This prospectus supplement
updates and supplements the information in the accompanying prospectus and is not complete without and may not be delivered or utilized
except in combination with, the accompanying prospectus, including any amendments or supplements thereto. This prospectus supplement
should be read in conjunction with the accompanying prospectus and if there is any inconsistency between the information in the accompanying
prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.
Investing in the securities
offered by this prospectus supplement involves substantial risks. You should carefully consider the risks described under the “Risk
Factors” section of this prospectus supplement beginning on page S-2 and similar sections in our filings with the Securities
and Exchange Commission (the “Commission”) incorporated by reference herein before buying any of the shares of Common Stock
offered hereby.
Neither the Commission
nor any other regulatory body has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus
supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.
The date of this prospectus supplement is July
12, 2024.
TABLE OF CONTENTS
Prospectus Supplement
Prospectus
IMPORTANT NOTICE ABOUT
INFORMATION IN THIS
PROSPECTUS SUPPLEMENT AND THE ACCOMPANYING PROSPECTUS
This document is in two parts.
The first part is this prospectus supplement, which describes the specific terms of this offering and also adds to and updates information
contained in the accompanying prospectus and the documents incorporated by reference therein. The second part is the accompanying prospectus,
which gives more general information, some of which may not apply to the offering made pursuant to this prospectus supplement. Generally,
when we refer only to the “prospectus,” we are referring to both parts combined. If the information about this offering varies
between this prospectus supplement and the accompanying prospectus, you should rely on the information in this prospectus supplement.
Any statement made in this
prospectus supplement or in a document incorporated or deemed to be incorporated by reference into this prospectus supplement will be
deemed to be modified or superseded for purposes of this prospectus supplement to the extent that a statement contained in this prospectus
supplement or in any other subsequently filed document that is also incorporated by reference into this prospectus supplement modifies
or supersedes that statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute
a part of this prospectus supplement.
We urge you to carefully
read this prospectus supplement and the accompanying prospectus, and the documents incorporated by reference therein, before
buying any of the securities being offered under this prospectus supplement. You should rely only on the information contained in this
prospectus supplement and the accompanying prospectus or incorporated by reference therein or contained in a freewriting prospectus
we have prepared. We have not authorized anyone to provide you with different information. No dealer, salesperson or other person is authorized
to give any information or to represent anything not contained in this prospectus supplement and the accompanying prospectus. You should
not rely on any unauthorized information or representation. This prospectus supplement is an offer to sell only the securities offered
hereby, and only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this
prospectus supplement and the accompanying prospectus is accurate only as of the date on the front of the applicable document and that
any information we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless
of the date of delivery of this prospectus supplement or the accompanying prospectus, or any sale of a security.
Neither we, nor any of our
respective representatives are making any representation to you regarding the legality of an investment in our securities by you under
applicable laws. You should consult with your own advisors as to legal, tax, business, financial and related aspects of an investment
in our securities. References in this prospectus supplement to the “Company,” “Danimer,” “we,” “our,”
or “us,” refer to Danimer Scientific, Inc. unless otherwise stated or the context otherwise requires.
RISK FACTORS
Investing in our securities
involves risks. Our business is influenced by many factors that are difficult to predict and beyond our control and that involve uncertainties
that may materially affect our results of operations, financial condition or cash flows, or the value of our Common Stock and other securities.
These risks and uncertainties include those described below, as well as in the risk factors and other sections of the documents that are
incorporated by reference in this prospectus supplement, including “Part I, Item 1A. Risk Factors” in our Annual Report on
Form 10-K for the fiscal year ended December 31, 2023. You should carefully consider these risks and uncertainties and all the information
contained or incorporated by reference in this prospectus supplement and the accompanying prospectus before you invest in our common stock.
Future
sales or other dilution of our equity may adversely affect the market price of our Common Stock.
We may issue additional shares
of Common Stock to the public or under our employee and director compensation plans. We regularly evaluate opportunities to access capital
markets, taking into account our capital needs, financial condition, strategic plans and other relevant considerations. The issuance of
additional shares of Common Stock or common equivalent securities in future equity offerings will dilute the ownership interest of our
existing stockholders and may depress the trading value of the Warrants or our Common Stock. There can be no assurances that we will not
in the future determine that it is advisable or necessary to issue additional shares of Common Stock or other securities convertible or
exercisable for shares of Common Stock to fund our business needs. We also expect to continue to use equity and stock options to compensate
our employees and directors and others. The market price of our Common Stock could decline significantly as a result of such offerings
or issuances, or the perception that such offerings or issuances could occur.
The exercise of our outstanding options
and warrants will dilute stockholders and could decrease our stock price.
The exercise of our outstanding
options and warrants may adversely affect our stock price due to sales of a large number of shares or the perception that such sales could
occur. These factors also could make it more difficult to raise funds through future offerings of our securities and could adversely impact
the terms under which we could obtain additional equity capital. Exercise of outstanding options and warrants or any future issuance of
additional shares of Common Stock or other securities, including, but not limited to preferred stock, options, warrants, restricted stock
units or other derivative securities convertible into our Common Stock, may result in significant dilution to our stockholders and may
decrease our stock price.
Because we do not currently intend to pay
cash dividends on our Common Stock, stockholders will benefit from an investment in our Common Stock only if it appreciates in value.
We do not currently anticipate
paying any cash dividends on shares of our Common Stock. Any determination to pay dividends in the future will be made by our Board of
Directors and will depend upon results of operations, financial conditions, contractual restrictions, restrictions imposed by applicable
law, and other factors our Board of Directors deems relevant. Accordingly, realization of a gain on stockholders’ investments will
primarily depend on the appreciation of the price of our Common Stock. There is no guarantee that our Common Stock will appreciate in
value or even maintain the price at which stockholders purchased their shares.
We will require additional capital to support
business growth, and this capital might not be available on favorable terms, or at all.
Our operations or expansion
efforts will require substantial additional financial, operational, and managerial resources and we will need to raise additional funds
to expand our operations. If we obtain additional funding in the future, we may seek debt financing or obtain additional equity capital.
Additional capital may not be available to us, or may only be available on terms that adversely affect our existing stockholders, or that
restrict our operations.
For example, if we raise
additional funds through issuances of equity or convertible debt securities, our existing stockholders could suffer dilution, and any
new equity securities we issue could have rights, preferences, and privileges superior to those of holders of our Common Stock. Upon liquidation,
holders of our debt securities and lenders with respect to other borrowings will receive distributions of our available assets prior to
the holders of our Common Stock. Since our decision to issue securities in any future offering will depend on market conditions and other
factors beyond our control, we cannot predict or estimate the amount, timing or nature of our future offerings. Thus, our stockholders
bear the risk of our future offerings reducing the market price of our Common Stock.
There can be no assurance
that we will be able to comply with the continued listing standards of the NYSE.
On
May 21, 2024, we were notified by NYSE Regulation that we were not in compliance with the NYSE’s continued listing criteria because
the average closing price of our Common Stock was less than $1.00 over a 30-day consecutive trading day period ending May 20, 2024. We
are subject to a 180-day cure period and we cannot be certain that we will be able to cure our non-compliance, absent completing a reverse-stock
split, which would require the approval of our stockholders.
If
the NYSE delists our securities from trading on its exchange for failure to meet the listing standards, we and our securityholders could
face significant material adverse consequences including:
| ● | a limited availability of market quotations for our securities; |
| ● | a determination that our common stock is a “penny stock,”
which will require brokers trading in common stock to adhere to more stringent rules, possibly resulting in a reduced level of trading
activity in the secondary trading market for shares of our common stock; |
| ● | a limited amount of analyst coverage; |
| ● | a decreased ability to issue additional securities or obtain
additional financing in the future; and |
| ● | the occurrence of a “Fundamental Change” under
the Indenture governing our 3.250% convertible senior notes due 2026, in which case the holders of the convertible notes could require
us to repurchase their convertible notes at a purchase price equal to the principal amount of and any accrued and unpaid interest on
such convertible notes. |
USE OF PROCEEDS
We will not receive any proceeds
from this offering.
PLAN OF DISTRIBUTION
We intend to issue up to
5,939,560 shares of our Common Stock directly to the Advisor from time to time in consideration of the Services provided by the Advisor
to the Company in connection with the Company’s distribution of transferable Warrants (each, a “Warrant” and, collectively,
the “Warrants”) to holders of (i) shares of Common Stock, (ii) 3.250% Convertible Senior Notes due 2026 (on an as-converted
basis), and (iii) pre-funded common stock purchase warrants dated March 25, 2024 (on an as-exercised basis). The Company will receive
proceeds from the exercise of the Warrants for cash. If Warrant holders exercise Warrants through the surrender of certain notes specified
by us (“Designated Notes”), the amount of the Company’s outstanding debt will be reduced. We will issue these shares
of Common Stock from time to time to Advisor in partial satisfaction of the advisory fee payable to Advisor following exercise of Warrants,
whether exercised for cash or by surrendering Designated Notes.
DESCRIPTION OF COMMON STOCK
A description of our Common
Stock is set forth under the heading “Description of Common Stock” starting on page 3 of the accompanying prospectus. On
July 11, 2024, we had 118,031,700 shares of Common Stock outstanding.
PROSPECTUS
DANIMER SCIENTIFIC, INC.
$350,000,000
Common Stock
Preferred Stock
Debt Securities
Guarantees of Debt Securities
Warrants
This prospectus provides a
general description of securities of Danimer Scientific, Inc. (the “Company,” “Danimer,” “we,” “our,”
and “us”) that we may offer and the general manner in which we will offer them. We may offer, issue and sell, from time to
time, in one or more offerings and series, together or separately, shares of our common stock, shares of our preferred stock, debt securities,
guarantees of debt securities or warrants up to an aggregate amount of $350,000,000.
Each time any of our securities
is offered using this prospectus, we will provide a prospectus supplement and attach it to this prospectus. The applicable prospectus
supplement will contain more specific information about the offering. The applicable prospectus supplement will also contain information,
where appropriate, about material United States federal income tax consequences relating to, and any listing on a securities exchange
of, the debt or equity securities covered by the prospectus supplement. The applicable prospectus supplement may also add, update or change
the information in this prospectus and will also describe the specific manner in which we will offer such securities.
This prospectus may not
be used to offer or sell securities without a prospectus supplement which includes a description of the method and terms of the offering.
You should carefully read
this prospectus and any accompanying prospectus supplement, together with the documents we incorporate by reference, before you invest
in our securities.
We may offer and sell these
securities to or through one or more underwriters, dealers and agents or directly to purchasers, as designated from time to time, or through
a combination of these methods, on a continuous or delayed basis. We reserve the sole right to accept, and together with any agents, dealers
and underwriters, reserve the right to reject, in whole or in part, any proposed purchase of securities. The names of any underwriters,
dealers or agents will be included in a prospectus supplement. If any agents, dealers or underwriters are involved in the sale of any
securities, the applicable prospectus supplement will set forth any applicable commissions or discounts. The applicable prospectus supplement
will provide the specific terms of the plan of distribution.
Our common stock is listed
on the New York Stock Exchange under the symbol “DNMR.” We will provide information in any applicable prospectus supplement
regarding any listing of securities other than shares of our common stock on any securities exchange.
Investing in our securities
involves a high degree of risks. Please refer to the “Risk Factors” section beginning on page 2 of this prospectus, “Item
1A – Risk Factors” of our most recent Annual Report on Form 10-K incorporated by reference herein, and under similar headings
in the applicable prospectus supplement and any other documents that are incorporated by reference herein or therein, for a description
of the risks you should consider when evaluating this investment.
Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus
is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus is June 5, 2024
TABLE OF CONTENTS
ABOUT THIS PROSPECTUS
This prospectus is part of
a “shelf” registration statement on Form S-3 that we filed with the Securities and Exchange Commission, or the “SEC”,
under the Securities Act of 1933, as amended, or the Securities Act, using a “shelf” registration process. Under this shelf
registration process, we may, from time to time, offer and/or sell, in one or more offerings and series, together or separately, shares
of our common stock, preferred stock, debt securities, guarantees of debt securities or warrants up to an aggregate amount of $350,000,000.
This prospectus only provides you with a general description of the securities that we may offer. Each time we offer and sell any of our
securities, we will provide a prospectus supplement and attach it to this prospectus. The prospectus supplement will contain more specific
information about the terms of the securities and the offering. The applicable prospectus supplement will also contain information, where
appropriate, about material United States federal income tax consequences relating to, and any listing on a securities exchange of, the
debt or equity securities covered by the prospectus supplement. The prospectus supplement may also add, update or change information contained
in this prospectus. Any statement that we make in this prospectus will be modified or superseded by any inconsistent statement made by
us in a prospectus supplement. This prospectus and the prospectus supplements provide you with a general description of the Company and
our securities. Before purchasing any of our securities, you should read both this prospectus and any accompanying prospectus supplement
together with the additional information described under the headings “Where You Can Find More Information” and “Incorporation
of Certain Information by Reference.”
You should rely only on the
information contained in this prospectus or any prospectus supplement and those documents incorporated by reference in this prospectus
or any accompanying prospectus supplement. We have not authorized anyone to provide you with information that is in addition to, or different
from, that contained in this prospectus or any accompanying prospectus supplement. If anyone provides you with different or additional
information, you should not rely on it. This prospectus may only be used where it is legal to sell these securities, and we have not authorized
anyone to make any representations in connection with an offering other than those contained or incorporated by referenced in this prospectus
or any accompanying prospectus supplement. Neither this prospectus nor any prospectus supplement is an offer to sell, or a solicitation
of an offer to buy, in any state where the offer or sale is prohibited. The information in this prospectus, any prospectus supplement
or any document incorporated herein or therein by reference is accurate as of the date contained on the cover of such documents. Neither
the delivery of this prospectus or any prospectus supplement, nor any sale made under this prospectus or any prospectus supplement will,
under any circumstances, imply that the information in this prospectus or any prospectus supplement is correct as of any date after the
date of this prospectus or any such prospectus supplement.
References in this prospectus
to the “Company,” “Danimer,” “we,” “our,” and “us,” refer to Danimer Scientific,
Inc.
FORWARD-LOOKING STATEMENTS
Certain statements included
in this prospectus, any accompanying prospectus supplement and the documents incorporated by reference herein and therein are “forward-looking
statements” within the meaning of the federal securities laws. Forward-looking statements are made based on our expectations and
beliefs concerning future events impacting the Company and therefore involve a number of risks and uncertainties. In addition, any statements
that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions,
are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,”
“estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,”
“potential,” “predict,” “project,” “should,” “would” and similar expressions
may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. We
caution that forward-looking statements are not guarantees and that actual results could differ materially from those expressed or implied
in the forward-looking statements.
Potential risks and uncertainties
that could cause the actual results of operations or financial condition of the Company to differ materially from those expressed or implied
by forward-looking statements in this prospectus, any accompanying prospectus supplement and the documents incorporated herein and therein
include, but are not limited to the impact on our business, operations and financial results of
pandemics, such as the COVID-19 pandemic, and the ongoing conflicts in Ukraine and the Middle East (each of which, among other things,
may affect many of the items listed below); the demand for our products and services; revenue growth; effects of competition; supply chain
and technology initiatives; inventory and in-stock positions; state of the economy; state of the credit markets, including mortgages,
home equity loans, and consumer credit; impact of tariffs; demand for credit offerings; management of relationships with our employees,
suppliers and vendors, and customers; international trade disputes, natural disasters, public health issues (including pandemics and related
quarantines, shelter-in-place orders, and similar restrictions), and other business interruptions that could disrupt supply or delivery
of, or demand for, our products or services; continuation of equity programs; net earnings performance; earnings per share; capital allocation
and expenditures; liquidity; return on invested capital; expense leverage; stock-based compensation expense; commodity price inflation
and deflation; the ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries,
claims, and litigation; the effect of accounting charges; the effect of adopting certain accounting standards; the impact of regulatory
changes; financial outlook; and the integration of acquired companies into our organization and the ability to recognize the anticipated
synergies and benefits of those acquisitions. More information on potential factors that could affect the Company’s financial
results is included from time to time in the Company’s public reports filed with the Securities and Exchange Commission, including
the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. All forward-looking statements
included in this prospectus are based upon information available to the Company as of the date of this prospectus, and speak only as the
date hereof. We assume no obligation to update any forward-looking statements to reflect events or circumstances after the date of this
prospectus.
You should also read carefully
the factors described or referred to in the “Risk Factors” section of this prospectus, any accompanying prospectus supplement
and the documents incorporated by reference herein and therein, to better understand the risks and uncertainties inherent in our business
and underlying any forward-looking statements. Any forward-looking statements that we make in this prospectus, any accompanying prospectus
supplement and the documents incorporated by reference herein as well as other written or oral statements by us or our authorized officers
on our behalf, speak only as of the date of such statement, and we undertake no obligation to update such statements. Comparisons of results
for current and any prior periods are not intended to express any future trends or indications of future performance, unless expressed
as such, and should only be viewed as historical data.
THE COMPANY
Company Overview
We
are a performance polymer company specializing in bioplastic replacements for traditional petroleum-based plastics. Applications
for biopolymers include additives, aqueous coatings, fibers, filaments, films, thermoforming, and injection-molded articles. We bring
together innovative technologies to deliver biodegradable bioplastic materials to global consumer product companies. We believe that we
are the only commercial company in the bioplastics market to combine the production of a base polymer along with the reactive extrusion
capacity in order to give customers a “drop-in” replacement for a wide variety of petroleum-based plastics. We have core competencies
in polymer formulation and application development, fermentation process engineering, thermocatalysis, chemical engineering and polymer
science. In addition, we have created an extensive intellectual property portfolio to protect our innovations that together with our technology,
serves as a valuable foundation for our business and for future industry collaborations.
Market Overview
Globally,
over 800 billion pounds of plastic are produced each year. Bioplastics are a key segment of the
plastics industry and provide renewably-sourced products, which are compostable or biodegradable replacements for traditional petroleum-based
plastics. Bioplastics are used in a wide range of applications, including packaging, adhesives, food additives, food service items and
many others. The bioplastics industry is diverse and rapidly evolving. As companies continue to innovate new bioplastic products to meet
existing and future customer needs, we expect the industry to expand substantially.
We
primarily market our products to consumer packaging brand owners, converters and manufacturers in the plastics industry seeking to address
environmental, public health, renewability, composting and biodegradability concerns arising from customer perceptions and expectations,
government regulations, or other reasons.
Corporate Overview
The
Company (formerly Live Oak Acquisition Corp. and referred to as “Live Oak” when describing the period prior to the consummation
of the Business Combination described below) was incorporated in Delaware on May 24, 2019 as a special purpose acquisition company, or
SPAC, formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, recapitalization, reorganization,
or similar business combination with one or more businesses. Live Oak competed its initial public offering in May 2020. On December 29,
2020 (“Closing Date”), the Company consummated a business combination (“Business Combination”), pursuant to which
the Company acquired all of the outstanding capital stock of Meredian Holdings Group, Inc. (“Meredian Holdings Group” or “MHG”)
through the exchange of MHG common stock for Live Oak Class A common stock. The Business Combination was effected through the merger of
Green Merger Corp., a wholly owned subsidiary of Live Oak, with and into MHG, with MHG surviving the merger as a wholly owned subsidiary
of Live Oak.
In
connection with the closing of the Business Combination, the Company changed its name from Live Oak Acquisition Corp. to Danimer Scientific,
Inc.
The
following description of our business describes the business historically operated by Meredian Holdings Group and its subsidiaries under
the “Danimer Scientific” name as an independent enterprise prior to the Business Combination (“Legacy Danimer”)
and is operated by the Company following the consummation of the Business Combination.
We,
through our principal operating subsidiaries, Meredian, Inc., Meredian Bioplastics, Inc., Danimer Scientific, L.L.C., Danimer Bioplastics,
Inc., Danimer Scientific Kentucky, Inc., and Novomer, Inc., bring together innovative technologies to deliver biodegradable bioplastic
materials to global consumer product companies.
Our
headquarters are located at 140 Industrial Boulevard, Bainbridge, Georgia 39817 and our telephone number is (229) 243-7075.
Our
website address is www.danimerscientific.com. The content contained in, or that can be accessed through, our website is not part of this
prospectus (other than the documents that we file with the SEC that are expressly incorporated by reference into this prospectus). See
“Where You Can Find More Information” and “Incorporation of Certain Information by Reference.”
RISK FACTORS
Investing
in our securities involves a high degree of risk. Please carefully consider the risk factors described in our periodic and current reports
filed with the SEC, which are incorporated by reference in this prospectus, as well as any risks that may be set forth in or incorporated
by reference into the prospectus supplement relating to a specific security. Before making an investment decision, you should carefully
consider these risks as well as other information we include or incorporate by reference in this prospectus or include in any applicable
prospectus supplement. The risks and uncertainties we have described are not the only risks and uncertainties we face. Additional risks
and uncertainties not presently known to us or that we currently deem immaterial may also affect our business operations. The occurrence
of any of these risks could materially affect our business, results of operations or financial condition and cause the value of our securities
to decline. You could lose all or part of your investment.
USE OF PROCEEDS
The
use of proceeds from the sale of our securities will be specified in the applicable prospectus supplement.
Unless
stated otherwise in an accompanying prospectus supplement, we will use the net proceeds from the sale of securities described in this
prospectus for general corporate purposes.
When
a particular series of securities is offered, the accompanying prospectus supplement will set forth our intended use for the net proceeds
received from the sale of those securities. Pending application for specific purposes, the net proceeds may be temporarily invested in
marketable securities. The precise amounts and timing of the application of proceeds will depend upon our funding requirements and the
availability of other funds. Except as mentioned in any prospectus supplement, specific allocations of the proceeds to such purposes will
not have been made at the date of that prospectus supplement.
DESCRIPTION OF COMMON STOCK
The
following description of our common stock does not purport to be complete and is subject in all respects to applicable Delaware law and
qualified by reference to the provisions of our Fourth Amended and Restated Certificate of Incorporation, as amended (the “Certificate
of Incorporation”), and Second Amended and Restated Bylaws, as amended (the “Bylaws”). Copies of our Certificate of
Incorporation and Bylaws are incorporated by reference and will be sent to stockholders upon request. Please read “Where You Can
Find More Information” and “Incorporation of Certain Information by Reference” to find out how you obtain a copy of
those documents. We encourage you to read carefully this prospectus, the Certificate of Incorporation, the Bylaws and the other documents
we refer to herein for a more complete understanding of the Company’s common stock.
Authorized and Outstanding Common Stock
The
Certificate of Incorporation authorizes the issuance of 200,000,000 shares of Class A Common Stock, $0.0001 par value per share (“Common
Stock”), and 10,000,000 shares of undesignated preferred stock, $0.0001 par value. As of May 10, 2024, there were 116,443,200 shares
of Common Stock and no shares of preferred stock outstanding.
Voting Power
Except
as otherwise required by law or as otherwise provided in any certificate of designation for any series of preferred stock, the holders
of Common Stock possess all voting power for the election of our directors and all other matters requiring stockholder action. Holders
of Common Stock are entitled to one vote per share on matters to be voted on by stockholders. Generally,
all matters to be voted on by stockholders must be approved by a majority (or, in the case of election of directors, by a plurality) of
the votes entitled to be cast by all stockholders present in person or represented by proxy, voting together as a single class.
Dividends
Holders
of Common Stock will be entitled to receive such dividends, if any, as may be declared from time to time by our Board of Directors (the
“Board”) in its discretion out of funds legally available therefor. In no event will any stock dividends or stock splits
or combinations of stock be declared or made on Common Stock unless the shares of Common Stock at the time outstanding are treated equally
and identically. We have not paid any cash dividends on the Common Stock to date. We may retain future earnings, if any, for future operations,
expansion and debt repayment and have no current plans to pay cash dividends for the foreseeable future. Any decision to declare
and pay dividends in the future will be made at the discretion of the Board and will depend on, among other things, our results of operations,
financial condition, cash requirements, contractual restrictions and other factors that the Board may deem relevant. In addition, our
ability to pay dividends may be limited by covenants of any existing and future outstanding indebtedness we or our subsidiaries incur.
Liquidation, Dissolution and Winding Up
In
the event of our voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up, the holders of the common stock
will be entitled to receive an equal amount per share of all of our assets of whatever kind available for distribution to stockholders,
after the rights of the holders of the preferred stock have been satisfied.
Preemptive or Other Rights
Our
stockholders have no preemptive or other subscription rights and there are no sinking fund or redemption provisions applicable to Common
Stock.
Election of Directors
The
Bylaws provide that our business and affairs be managed by the Board. Our Board is composed of a single class of eleven directors, each
of whom will generally serve for a term of one year. There is no cumulative voting with respect to the election of directors, with the
result that the holders of more than 50% of the shares voted for the election of directors can elect all of the directors.
DESCRIPTION OF PREFERRED
STOCK
The
following is a description of certain general terms and provisions of our preferred stock. The particular terms of any series of preferred
stock offered by us will be described in a prospectus supplement relating to such offering. The following description of our preferred
stock does not purport to be complete and is subject in all respects to applicable Delaware law and qualified by reference to the provisions
of our Certificate of Incorporation, Bylaws and the certificate of designation relating to each series of our preferred stock, which will
be filed with the Securities and Exchange Commission at or prior to the time of issuance of such series of preferred stock.
Our
Certificate of Incorporation authorizes our Board to issue, without further stockholder approval, up to 10,000,000 shares of preferred
stock in one or more series, having a par value of $0.0001 per share. As of the date of this prospectus, no shares of our preferred stock
were outstanding.
Our
Board is authorized to fix the designation and relative rights for each series of preferred stock, and the applicable prospectus supplement
will set forth with respect to such series, the following information:
| ● | any stated redemption and liquidation values or preference per share; |
| ● | any sinking fund provisions; |
| ● | any conversion or exchange provisions; |
| ● | any participation rights; |
| ● | the terms of any other preferences, limitations and restrictions, as are
stated in the resolutions adopted by our Board and as are permitted by the Delaware General Corporation Law (the “DGCL”). |
The transfer agent and registrar
for each series of preferred stock will be described in the applicable prospectus supplement.
DESCRIPTION OF DEBT SECURITIES
The debt securities may be
senior debt securities or subordinated debt securities. The senior debt securities and the subordinated debt securities are together referred
to in this prospectus as the “debt securities.” The form of indenture is filed as an exhibit to the registration statement
of which this prospectus forms a part. We will include in a supplement to this prospectus the specific terms of each series of debt securities
being offered. The statements and descriptions in this prospectus or in any prospectus supplement regarding provisions of the debt securities
and the indenture are summaries thereof, do not purport to be complete and are subject to, and are qualified in their entirety by reference
to, all of the provisions of the indenture (and any amendments or supplements we may enter into from time to time which are permitted
under such indenture) and the debt securities, including the definitions therein of certain terms.
Unless otherwise specified
in a prospectus supplement, the debt securities will be our direct unsecured obligations. The indenture does not limit the aggregate principal
amount of debt securities that we may issue and provides that we may issue debt securities from time to time in one or more series, in
each case with the same or various maturities, at par or at a discount. Unless indicated in a prospectus supplement, we may issue additional
debt securities of a particular series without the consent of the holders of the debt securities of such series outstanding at the time
of the issuance. Any such additional debt securities, together with all other outstanding debt securities of that series, will constitute
a single series of debt securities under the indenture.
We will set forth in a prospectus
supplement (including any pricing supplement or term sheet) relating to any series of debt securities being offered the aggregate principal
amount and the following terms of the debt securities, if applicable:
| ● | The title and ranking of the debt securities
(including the terms of any subordination provisions); |
| ● | the price or prices (expressed as a percentage
of the principal amount) at which we will sell the debt securities; |
| ● | covenants that we will adhere to in connection
with the issuance and maintenance of debt securities; |
| ● | events of default, acceleration, waiver of defaults,
and related remedies, rights, and duties; |
| ● | form, denomination, issuance, registration, transfer,
and replacement of debt securities; |
| ● | guarantees of the debt securities of that series,
if any, including the terms of subordination, if any, of such guarantees; |
| ● | any other terms of the debt securities, which
may supplement, modify or delete any provision of the indenture as it applies to that series, including any terms that may be required
under applicable law or regulations or advisable in connection with the marketing of the securities; and |
| ● | satisfaction and discharge of debt securities. |
We may issue debt securities
that provide for an amount less than their stated principal amount to be due and payable upon declaration of acceleration of their maturity
pursuant to the terms of the indenture. We will provide you with information on the federal income tax considerations and other special
considerations applicable to any of these debt securities in the applicable prospectus supplement.
DESCRIPTION OF GUARANTEES OF THE DEBT SECURITIES
If specified in the applicable
prospectus supplement, certain of our subsidiaries will guarantee the debt securities. The particular terms of any guarantee will be described
in the related prospectus supplement. Any guarantees will be joint and several and full and unconditional obligations of the guarantors.
The obligations of each guarantor under its guarantee will be limited as necessary to prevent that guarantee from constituting a fraudulent
conveyance or fraudulent transfer under applicable law.
DESCRIPTION OF WARRANTS
A warrant is a security that
gives the holder the right, upon exercise of the warrant, to purchase a specified number of securities at a specified exercise price,
during a specified exercise period, which is subject to adjustment upon the occurrence of specified events. We may issue warrants for
the purchase of our common stock, preferred stock or debt securities or any combination thereof. Warrants may be issued independently
or together with our common stock, preferred stock or debt securities and may be attached to or separate from any such offered securities.
Each series of warrants will be issued under a separate warrant agreement to be entered into between us and a bank or trust company, as
warrant agent. The warrant agent will act solely as our agent in connection with the warrants. The warrant agent will not have any obligation
or relationship of agency or trust for or with any holders or beneficial owners of warrants. Warrants will be offered and exercisable
for United States dollars only. Warrants will be issued in registered form only. The particular terms of any warrants will be described
in the related prospectus supplement.
Anti-Takeover
Effects of CERTAIN Provisions of Delaware Law and
Our Certificate of Incorporation and Bylaws
Certain provisions of the
Certificate of Incorporation and Bylaws could have an anti-takeover effect. These provisions are intended to enhance the likelihood of
continuity and stability in the composition of the Board and in the policies formulated by the Board and to discourage an unsolicited
takeover of us if the Board determines that such takeover is not in the best interests of us and our stockholders. However, these provisions
could have the effect of discouraging certain attempts to acquire us or remove incumbent management even if some or a majority of stockholders
deemed such an attempt to be in their best interests.
The provisions in the Certificate
of Incorporation and the Bylaws include: (a) advance notice requirements for special meetings and the Board’s ability to solicit
additional information reasonably foreseeable to be material to a stockholder’s decision about the nominees or a stockholder proposal;
(b) a procedure which requires stockholders to nominate directors in advance of a meeting to elect such directors; (c) the authority
to issue additional shares of common stock and/or preferred stock without stockholder approval; (d) the number of directors on our Board
will be fixed exclusively by the Board; (e) any newly created directorship or any vacancy in our Board resulting from any increase in
the authorized number of directors or the death, disability, resignation, retirement, disqualification, removal from office or other cause
will be filled solely by the affirmative vote of a majority of the directors then in office, even if less than a quorum; and (f) our Bylaws
may be amended by our Board.
The DGCL contains statutory
“anti-takeover” provisions, including Section 203 of the DGCL which applies automatically to a Delaware corporation unless
that corporation elects to opt-out as provided in Section 203. We, as a Delaware corporation, have not elected to opt out of Section 203
of the DGCL. Under Section 203 of the DGCL, a stockholder acquiring more than 15% of the outstanding voting shares of a corporation
(an “Interested Stockholder”) but less than 85% of such shares may not engage in certain business combinations with the corporation
for a period of three years subsequent to the date on which the stockholder became an Interested Stockholder unless prior to such date,
the board of directors of the corporation approves either the business combination or the transaction which resulted in the stockholder
becoming an Interested Stockholder, or the business combination is approved by the board of directors and by the affirmative vote of at
least 66 2/3% of the outstanding voting stock that is not owned by the Interested Stockholder.
Limitation of Liability and Indemnification
of Officers and Directors
Pursuant to provisions of
the DGCL, we have adopted provisions in our Certificate of Incorporation that provide that our directors shall not be personally liable
for monetary damages to us or our stockholders for a breach of fiduciary duty as a director to the full extent that the Securities Act
permits the limitation or elimination of the liability of directors.
We have in effect a directors
and officers liability insurance policy indemnifying our directors and officers and the directors and officers of our subsidiaries within
a specific limit for certain liabilities incurred by them, including liabilities under the Securities Act. We pay the entire premium of
this policy. Our Certificate of Incorporation also contains a provision for the indemnification by us of all of our directors and officers,
to the fullest extent permitted by the DGCL.
Exclusive Forum
Our Bylaws provide that, unless
we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall, to the fullest extent
permitted by law, be the sole and exclusive forum for (a) any derivative action or proceeding brought on behalf of the Company, (b) any
action asserting a claim of breach of a fiduciary duty owed by any director, officer, other employee or stockholder of the Company to
the Company or the Company’s stockholders, (c) any action asserting a claim arising pursuant to any provision of the DGCL, the Certificate
of Incorporation, or Bylaws or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware, (d) any action
asserting a claim governed by the internal affairs doctrine; or (e) any action asserting an “internal corporate claim” as
that term is defined in Section 115 of the DGCL, shall be a state court located within the State of Delaware (or, if no state court
located within the State of Delaware has jurisdiction, the federal district court for the District of Delaware). Any person or entity
purchasing or otherwise acquiring any interest in shares of our stock shall be deemed to have notice of and consented to the foregoing
forum selection provisions.
PLAN OF DISTRIBUTION
We may sell securities
in any one or more of the following ways (or in any combination) from time to time:
| ● | to or through one or more underwriters or dealers; |
| ● | directly to a limited number of purchasers or
to a single purchaser, including through a specific bidding, auction or other process; or |
| ● | through agents, brokers or dealers. |
The applicable prospectus
supplement will set forth the terms of the offering of such securities, including:
| ● | the name or names of any underwriters, dealers
or agents and the amounts of securities underwritten or purchased by each of them; |
| ● | the public offering price of the securities and
the proceeds to us and any discounts, commissions or concessions allowed or reallowed or paid to dealers; |
| ● | describing any compensation in the form of discounts,
concessions or commissions or otherwise received from us by each of such underwriter, dealer or agent and in the aggregate to all underwriters,
dealers and agents; |
| ● | identifying the amounts underwritten; |
| ● | identifying the nature of the underwriter’s
obligation to take the securities; |
| ● | identifying any over-allotment option under which
the underwriters may purchase additional securities from us; |
| ● | identifying any quotation systems or securities
exchanges on which the securities may be quoted or listed; and |
| ● | identifying any other facts material to the transaction. |
Any public offering price
and any discounts or concessions allowed or reallowed or paid to dealers may be changed from time to time.
We may effect the distribution
of the securities from time to time in one or more transactions either:
| ● | at a fixed price or at prices that may be changed; |
| ● | at market prices prevailing at the time of sale; |
| ● | at prices relating to such prevailing market
prices; or |
Any underwritten offering
may be on a best efforts or a firm commitment basis. If underwriters are used in the sale of any securities, the securities will be acquired
by the underwriters for their own account and may be resold from time to time in one or more transactions, including, without limitation,
negotiated transactions, at a fixed public offering price or at varying prices determined at the time of sale. The securities may be either
offered to the public through underwriting syndicates represented by managing underwriters, or directly by underwriters without a syndicate.
Generally, the underwriters’ obligations, if any, to purchase the securities will be subject to certain conditions precedent. Subject
to certain conditions, the underwriters will be obligated to purchase all of the securities if they purchase any of the securities (other
than any securities purchased upon exercise of any option to purchase additional securities or any over-allotment option). Any public
offering price and any discounts or concessions allowed, reallowed or paid to dealers may be changed from time to time.
If a dealer is used in an
offering of securities, we may sell the securities to the dealer, as principal. The dealer may then resell the securities to the public
at varying prices to be determined by the dealer at the time of sale. The prospectus supplement may set forth the name of the dealer and
the terms of the transactions.
We may sell the securities
directly or through agents that we designate from time to time. The applicable prospectus supplement will name any agent involved in the
offer or sale of the securities and will describe any commissions payable by us to the agent. Generally, any agent will be acting on a
best efforts basis for the period of its appointment.
We may also sell the securities
offered by any applicable prospectus supplement in “at-the-market offerings” within the meaning of Rule 415 of the Securities
Act, to or through a market maker or into an existing trading market, on an exchange or otherwise. If a broker is used in the sale of
the securities, the broker will not acquire the securities, and we will sell the securities directly to the purchasers in the applicable
market. The prospectus supplement will set forth the terms of the arrangements with the broker.
We may sell the securities
directly to one or more purchasers without using any underwriters, dealers or agents. In that event, no underwriters or agents would be
involved. In addition, we may enter into derivative, sale or forward sale transactions with third parties, or sell securities not covered
by this prospectus to third parties in privately negotiated transactions. If the applicable prospectus supplement indicates, in connection
with such a transaction, the third parties may, pursuant to this prospectus and the applicable prospectus supplement, sell securities
covered by this prospectus and the applicable prospectus supplement. If so, a third party may use securities borrowed from us or others
to settle such sales and may use securities received from us or others to settle those sales to close out any related short positions.
The third party in such sale transactions will be an underwriter and will be identified in the applicable prospectus supplement (or a
post-effective amendment). We may also loan or pledge securities covered by this prospectus and the applicable prospectus supplement to
third parties, who may sell the loaned securities or, in an event of default in the case of a pledge, sell the pledged securities pursuant
to this prospectus and the applicable prospectus supplement. We may also sell the securities directly, in which event, no underwriters
or agents will be involved.
In the sale of the securities,
underwriters, dealers or agents may receive compensation in the form of commissions, discounts or concessions from us. Underwriters,
dealers or agents may also receive compensation from the purchasers of securities for whom they act as agents or to whom they sell as
principals, or both. Any underwriters, broker-dealers and agents that participate in the distribution of the securities may be deemed
to be “underwriters” as defined in the Securities Act. Any commissions paid or any discounts or concessions allowed to any
such persons, and any profits they receive on resale of the securities, may be deemed to be underwriting discounts and commissions under
the Securities Act. Compensation as to a particular underwriter, dealer or agent might be in excess of customary commissions and will
be in amounts to be negotiated in connection with transactions involving securities. In effecting sales, broker-dealers engaged by us
may arrange for other broker-dealers to participate in the resales. Maximum compensation to any underwriters, brokers, dealers or agents
will not exceed any applicable FINRA limitations.
Agents, underwriters and dealers
may be entitled, under relevant agreements with us, to indemnification by us against certain liabilities, including liabilities under
the Securities Act, or to contribution with respect to payments which such agents, underwriters and dealers may be required to make
in respect thereof. The terms and conditions of any indemnification or contribution will be described in the applicable prospectus supplement.
Underwriters or agents may
purchase and sell the securities in the open market. These transactions may include over-allotments, stabilizing transactions, syndicate
covering transactions and penalty bids. Over-allotments involve sales in excess of the offering size, which creates a short position.
Stabilizing transactions consist of bids or purchases for the purpose of preventing or retarding a decline in the market price of the
securities and are permitted so long as the stabilizing bids do not exceed a specified maximum. Syndicate covering transactions involve
the placing of any bid on behalf of the underwriting syndicate or the effecting of any purchase to reduce a short position created in
connection with an offering. The underwriters or agents also may impose a penalty bid, which permits them to reclaim selling concessions
allowed to syndicate members or certain dealers if they repurchase the securities in stabilizing or covering transactions. These activities
may stabilize, maintain or otherwise affect the market price of the securities, which may be higher than the price that might otherwise
prevail in the open market. These activities, if begun, may be discontinued at any time. These transactions may be effected on any exchange
on which the securities are traded, in the over-the-counter market or otherwise.
Agents, dealers and underwriters
may be customers of, engage in transactions with, or perform services for us in the ordinary course of business.
The specific terms of any
lock-up provisions in respect of any given offering of common stock will be described in the applicable prospectus supplement.
The place and time of delivery
for securities will be set forth in the accompanying prospectus supplement for such securities. To comply with applicable state securities
laws, the securities offered by this prospectus will be sold, if necessary, in such jurisdictions only through registered or licensed
brokers or dealers. In addition, securities may not be sold in some states unless they have been registered or qualified for sale in the
applicable state or an exemption from the registration or qualification requirement is available and is complied with.
Unless otherwise specified
in the related prospectus supplement, each series of securities will be a new issue with no established trading market, other than the
common stock, which is listed on the New York Stock Exchange. Any common stock sold pursuant to a prospectus supplement will be listed
on the New York Stock Exchange, subject to applicable notices. We may elect to apply for quotation or listing of any other class or series
of our securities on a quotation system or an exchange but we are not obligated to do so. It is possible that one or more underwriters
may make a market in a class or series of our securities, but such underwriters will not be obligated to do so and may discontinue any
market making at any time without notice. Any such activities will be described in the prospectus supplement. Therefore, no assurance
can be given as to the liquidity of, or the trading market for, any other class or series of our securities.
WHERE YOU CAN FIND MORE INFORMATION
We
file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the
public over the Internet at the SEC’s website at www.sec.gov. Copies of certain information filed by us with the SEC
are also available on our website at www.danimerscientific.com. Information accessible on or through our website is not a
part of this prospectus (other than the documents that we file with the SEC that are expressly incorporated by reference into this prospectus).
This
prospectus and any prospectus supplement are part of a registration statement that we filed with the SEC and do not contain all of the
information in the registration statement. You should review the information and exhibits in the registration statement for further information
on us and our consolidated subsidiaries and the securities that we are offering. Forms of any indenture or other documents establishing
the terms of the offered securities are filed as exhibits to the registration statement of which this prospectus forms a part or under
cover of a Current Report on Form 8-K and incorporated in this prospectus by reference. Statements in this prospectus or any
prospectus supplement about these documents are summaries and each statement is qualified in all respects by reference to the document
to which it refers. You should read the actual documents for a more complete description of the relevant matters.
This
prospectus omits certain information that is contained in the registration statement on file with the SEC, of which this prospectus is
a part. For further information with respect to us and our securities, reference is made to the registration statement, including the
exhibits incorporated therein by reference or filed therewith. Statements herein contained concerning the provisions of any document are
not necessarily complete and, in each instance, reference is made to the copy of such document filed as an exhibit or incorporated by
reference to the registration statement. Each such statement is qualified in its entirety by such reference.
INCORPORATION OF CERTAIN INFORMATION BY REFERENCE
The SEC allows us to “incorporate
by reference” information from other documents that we file with it, which means that we can disclose important information to you
by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus. Information
in this prospectus supersedes information incorporated by reference that we filed with the SEC prior to the date of this prospectus, while
information that we file later with the SEC will automatically update and supersede the information in this prospectus. We incorporate
by reference into this prospectus and the registration statement of which this prospectus is a part the information or documents listed
below that we have filed with the SEC (Commission File No. 001-39280):
| ● | our Annual Report on Form 10-K for the year ended
December 31, 2023, filed with the SEC on March 29, 2024; |
| ● | our Quarterly Report on Form 10-Q for the quarter
ended March 31, 2024, filed with the SEC on May 7, 2024; |
| ● | the description of our common stock contained
in our Registration Statement on Form 8-A12B, filed with the SEC on May 4, 2020 under the Securities and Exchange Act of 1934, as amended
(the “Exchange Act”), including, without limitation, any amendment or report filed for the purpose of updating such description;
and |
| ● | our Current Reports on Form 8-K filed with
the Commission on January 18,
2024, January 29, 2024, March
25, 2024, April 22, 2024, May
3, 2024 and May 10, 2024 (in each case, excluding “furnished” and not “filed” information under Item
2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that are related to such items). |
We also incorporate by reference
any future filings (other than any filings or portions of such reports that are not deemed “filed” under the Exchange Act
in accordance with the Exchange Act and applicable SEC rules, including current reports furnished under Item 2.02 or Item 7.01 of Form
8-K and exhibits furnished on such form that are related to such items unless such Form 8-K expressly provides to the contrary) made with
the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, until we file a post-effective amendment which indicates the
termination of the offering of the securities made by this prospectus and the accompanying prospectus. Information in such future filings
updates and supplements the information provided in this prospectus and the accompanying prospectus. Any statements in any such future
filings will automatically be deemed to modify and supersede any information in any document we previously filed with the SEC that is
incorporated or deemed to be incorporated herein by reference to the extent that statements in the later filed document modify or replace
such earlier statements.
You may obtain copies of any
of these filings by contacting us at the address and telephone number indicated below.
Documents incorporated by
reference are available from us without charge, excluding all exhibits unless an exhibit has been specifically incorporated by reference
into this prospectus, by requesting them in writing or by telephone at:
Danimer Scientific, Inc.
Attention: Corporate Secretary
140 Industrial Boulevard
Bainbridge, Georgia 39817
(229) 243-7075
EXPERTS
The consolidated financial
statements of Danimer Scientific, Inc. as of December 31, 2023 and 2022, and for the years then ended, have been incorporated by reference
herein and in the registration statement in reliance upon the report of KPMG LLP, independent registered public accounting firm, incorporated
by reference herein, and upon the authority of said firm as experts in accounting and auditing.
LEGAL MATTERS
The validity of the securities
offered hereby will be passed upon for us by Kane Kessler, P.C., New York, New York. Any underwriters, dealers, or agents will be advised
of the other issues relating to any offering by their own legal counsel, which will be named in an accompanying prospectus supplement
relating to that offering.
Up To 5,939,560 Shares of Common Stock
Danimer Scientific, Inc.
PROSPECTUS SUPPLEMENT
July 12, 2024
Exhibit 107
Calculation of Filing
Fee Table
424(b)(2)
(Form Type)
DANIMER SCIENTIFIC,
INC.
(Exact Name of Registrant
as Specified in its Charter)
Table 1 - Newly
Registered Securities
| | |
Security
Type | |
Security
Class Title | |
Fee
Calculation Rule | | |
Amount
Registered | | |
Proposed
Maximum
Offering
Price Per
Security | | |
Maximum
Aggregate
Offering
Price | | |
Fee Rate | |
Amount of
Registration
Fee | |
| Fees to Be Paid | |
Equity | |
Common Stock, par value
$0.0001 per share (“Common Stock”) | |
| 457(c) | | |
| 5,939,560 | | |
$ | 0.5545 | (1) | |
$ | 3,293,486.02 | | |
$147.60 per
$1,000,000 | |
$ | 486.19 | |
| Fees Previously Paid | |
N/A | |
Common Stock | |
| 457(o) | | |
| | (2) | |
| | (2) | |
$ | 350,000,000 | (2) | |
$147.60 per
$1,000,000 | |
$ | 51,660 | (2) |
| Carry Forward Securities | |
N/A | |
N/A | |
| N/A | | |
| N/A | | |
| N/A | | |
| N/A | | |
| |
| N/A | |
| | |
| |
Total Offering Amounts | | |
| | | |
$ | 3,293,486.02 | | |
$147.60 per $1,000,000 | |
$ | 486.19 | |
| | |
| |
Total Fees Previously Paid | | |
| | | |
| | | |
| |
$ | 51,660 | (2)(3) |
| | |
| |
Total Fee Offsets | | |
| | | |
| | | |
| |
| | |
| | |
| |
Net Fee Due | | |
| | | |
| | | |
| |
$ | 0 | (2)(3) |
| (1) | Pursuant to Rule 457(c) under the Securities Act, the average
of the high low price reported on July 10, 2024 was $0.5545. |
| (2) | The registrant filed a Form S-3 Registration Statement (No.
333-279371) (the “Registration Statement”), filed on May 13, 2024 and declared effective on June 5, 2024, which registered
the offer and sale of an indeterminate number of certain securities, including of the types listed above (collectively, the “Shelf
Securities”), having an aggregate initial maximum offering price for the Shelf Securities not to exceed $350,000,000. In connection
with the filing of the Registration Statement, the registrant paid a filing fee of $51,660 with respect to the Shelf Securities calculated
in accordance with Rule 457(o) of the Securities Act of 1933 (the “Securities Act”), as amended. |
| (3) | At the time of the filing of the prospectus supplement to
which this exhibit is attached (the “Prospectus Supplement”), the registrant has $17,153 in unused filing fees associated
with the Registration Statement, after accounting for $233,785,749 of securities that were issued under the Registration Statement in
other offerings. Accordingly, the filing fee to be paid pursuant to the Prospectus Supplement is $486.19. Pursuant to Rule 457(b) under
the Securities Act, the balance of the filing fee of $51,660 paid with respect to the Shelf Securities at the time of the filing of the
Registration Statement will be applied to the $486.19 filing fee payable for the securities registered pursuant to the Prospectus Supplement,
and therefore the net fee due in connection with the filing of the Prospectus Supplement is $0. |
Danimer Scientific (NYSE:DNMR)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
Danimer Scientific (NYSE:DNMR)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024
